Author: devcuration

January 6, 2026 did not show up with confetti. It showed up with intent. Enable Injections secured a $30M strategic investment from Sanofi, and it reads less like a transaction and more like a long-running conversation reaching its next verse. When the same global pharma partner leads a Series B in 2018, backs a $215M Series C in 2022, and then comes back again, that is not habit. That is alignment forged under pressure. Enable Injections was built in Cincinnati by Michael D. Hooven, a founder who does not romanticize invention. More than 30 years in medical devices, 100+ issued…

When a road company bets on the data that tells the road the truth, you get progress without theatrics. Citylogix just secured a strategic investment from CRH Ventures, and if that feels inevitable, it is because this story has been compounding quietly since 2015. Founded as StreetScan and sharpened into Citylogix in 2025, this is a company that learned every crack, rut, and scar the hard way, then taught software how to remember it better than humans ever could. Citylogix did not grow by chasing headlines or frothy rounds. It grew by serving 450+ municipalities across the US and Canada,…

Mediar Therapeutics walked into 2026 like it had already read the room and decided patience was overrated. An oversubscribed $76M Series B, announced January 7, co-led by Amplitude Ventures and ICG, with Longwood Fund, Asahi Kasei Pharma Ventures, Alexandria Real Estate Trust, and the entire Series A syndicate showing up again. Capital does not chase noise at this altitude. It follows conviction, timing, and receipts. Founded in 2019 out of Massachusetts General Hospital and Brigham and Women’s Hospital, with Mass General Brigham Ventures laying the early foundation, Mediar Therapeutics went after fibrosis with a surgeon’s mindset, not a marketing one.…

Spiro Medical, Inc. did not arrive with fireworks. It arrived with oxygen. Founded in 2024 in Irvine, California, this is a medtech company built around a simple but uncomfortable truth: severe asthma is not just an inflammatory problem, it is a neurological one. Instead of stacking another drug on an already exhausted patient, Spiro Medical, Inc. went upstream, into the spinal cord, and asked a better question about control, signaling, and breathing itself. Pulmonary Neuromodulation sounds academic until you realize what it replaces. No daily inhalers. No injections on a calendar. No dependency disguised as maintenance. By adapting spinal cord…

January in Vegas has a way of exposing the difference between noise and signal. CES floods the room with promises, demos, and buzzwords chasing attention. Then a San Jose company named Sibros steps forward and calmly reminds everyone that modern vehicles are not finished products when they roll off the line. They are evolving systems. On January 6, 2026, Sibros secured $9M in growth funding led by Niterra Co., Ltd., and the timing mattered. This was not an announcement buried in a slow news cycle. It landed right in the middle of the global mobility conversation. Sibros was founded in…

Corsera Health, Inc. just stepped out of stealth with the kind of calm that makes experienced people lean forward. Boston-based, clinical-stage, and deliberately unflashy, this is not a company chasing noise. It is a company staring directly at the world’s most persistent killer and deciding prevention deserves real engineering. An $80M Series A does not change that posture. It sharpens it. The leadership tells you everything you need to know. John Maraganore, Ph.D. and Clive Meanwell, M.D. have spent decades doing things most people said would take longer, cost more, or never work. RNA interference as medicine. Cardiovascular drugs that…

Mental health spent decades talking about feelings like they were ghosts. Everyone knew they were real, everyone felt the impact, but the data trail went cold the second a session ended. Oasys Health was born out of that tension in July 2024, not as a softer take on care, but as a demand for evidence. New York grit, Harvard and Duke brains, and zero patience for medicine that cannot measure itself. Hashem Abdou saw the gap early. Coming out of biomedical engineering and computer science at Harvard, with real wearables research under his belt, the contrast was obvious. Cardiology runs…

Rakuten Medical just locked a $100M Series F on Jan 7, 2026, and this was not a quiet raise slipped in between meetings. Oversubscribed. 2x the original target. Total capital now sitting around $866.8M. San Diego address, global posture, and a biotech arc that started back in 2010 as Aspyrian Therapeutics. Miguel Garcia-Guzman did not build this company for fast applause. He built it for science that survives scrutiny, timelines that test patience, and outcomes that actually move needles in oncology. The inflection point came in 2013, when Hiroshi “Mickey” Mikitani stepped in, not as a brand-name investor chasing allocation,…

Mitera Biosciences did not come out of stealth waving its arms. It surfaced the way serious biology does, quietly, deliberately, with receipts. A $1.75 million seed round filed with the SEC, announced December 30, 2025, and a mission rooted in something most of modern immunology forgot to respect. The human body already knows how to tolerate what should not belong. Pregnancy figured it out long before biotech showed up with spreadsheets. Based in Bellevue, Washington, Mitera Biosciences is building safer alternatives to traditional immunosuppressive therapies for transplant rejection and autoimmune disease by studying that biological ceasefire. During pregnancy, the immune…

Array Labs, Inc. just raised a $20M Series A, and this is one of those rounds that does not shout because it does not need to. Palo Alto roots, founded in 2021, Y Combinator S22, and quietly building hardware that sees through clouds, darkness, and bad assumptions with equal indifference. Array Labs designs and manufactures space-based synthetic aperture radar systems that generate high-resolution 3D representations of Earth. Not postcard imagery. Not optimistic interpretations. Actual volumetric truth. Multiple small satellites flying in formation, acting together, creating depth where the industry has been content with flatness for decades. The Series A was…